Nav: Home

Anakinra does not seem to improve fatigue severity in women with chronic fatigue syndrome

March 06, 2017

1. Anakinra does not improve fatigue severity in women with chronic fatigue syndrome
Abstract: http://annals.org/aim/article/doi/10.7326/M16-2391

URL goes live when the embargo lifts

The anti-inflammatory biologic drug anakinra (interleukin-1 receptor antagonist) does not reduce fatigue severity in women with chronic fatigue syndrome (CFS). The findings of a randomized, placebo-controlled trial are published in Annals of Internal Medicine.

CFS is characterized by severe, persistent, and disabling fatigue. In order to fulfill the Centers for Disease Control and Prevention (CDC) criteria for CFS, patients have to report at least four of eight accompanying symptoms in addition to fatigue (headache, muscle plain, etc.). Interleukin-1 (IL-1), a pro-inflammatory cytokine, has been associated with CFS in some studies. There is extensive experience with blocking IL-1 in a variety of diseases with the IL-1 receptor antagonist anakinra. Several studies in inflammatory and non-inflammatory illnesses have assessed the effect of IL-1 inhibition on fatigue severity, and most have found positive effects of this intervention.

Researchers from Radboud University Medical Centre in the Netherlands conducted a randomized, placebo-controlled trial to evaluate the effects of anakinra injections versus placebo on fatigue severity in patients with CFS. Since CFS typically affects women, the researchers included only female patients to investigate a homogeneous group. Fifty women with severe fatigue leading to functional impairment were randomly assigned to receive daily anakinra injections (100 mg) or placebo for 4 weeks, followed by an additional 20 weeks of follow-up after treatment.

Fatigue severity, the primary outcome, was assessed via questionnaire at 4 and 24 weeks. The secondary outcomes of level of impairment, physical and social functioning, psychological distress, and pain severity were assessed at 4 and 24 weeks. The researchers found no clinically meaningful difference in fatigue severity with anakinra. They also found no statistically significant differences between groups for secondary outcomes. They conclude that if IL-1 plays a role in CFS, blocking it with anakinra has no effect.

Note: For an embargoed PDF, please contact Cara Graeff. To interview the author, Megan Roerink, MD, please contact nieuws@radboudumc.nl

2. Disrupting the flow of international medical graduates to the U.S. will have a negative effect on patient care
Abstract: http://annals.org/aim/article/doi/10.7326/M17-0505 URL goes live when the embargo lifts

A commentary published in Annals of Internal Medicine suggests that disrupting the flow of international medical graduates who come to the United States to complete their training will have a negative impact on patient care.

Currently, internationally educated physicians account for approximately one quarter of the practicing physician workforce in the U.S. They come to the U.S. for many reasons, including the desire to engage in care that, based on their home country resource constraints, is not available. While international medical graduates enter many different medical specialties, internal medicine is by far the most common. Over the past decade, there have been calls for the U.S. to train its own physicians and stop relying on economically underdeveloped nations to augment the workforce. However, there is no clear path to self-sufficiency. International graduates are needed to fill practice gaps left by U.S. graduates who may not choose careers in certain specialties or practice in undeserved areas.

In his commentary, William W. Pinsky, MD, President and CEO of the Educational Commission for Foreign Medical Graduates (ECFMG), located in Philadelphia, describes the current vetting process for international medical graduates and outlines their importance to quality healthcare delivery in the U.S. and the subsequent contribution to the safety of the country.

Note: For an embargoed PDF, please contact Cara Graeff. To interview the author, William Pinsky, MD, please contact Liz Ingram at eingraham@ecfmg.org or 215-823-2108.
-end-
Also new in this issue:

Developing Recommendations for Evidence-Based Clinical Preventive Services for Diverse Populations: methods of the U.S. Preventive Services Task Force

Kirsten Bibbins-Domingo, PhD, MD, MAS; Evelyn Whitlock, MD, MPH; Tracy Wolff, MD, MPH; Quyen Ngo-Metzger, MD, MPH; William R. Phillips, MD, MPH; Karina W. Davidson, PhD, MASc; Alex H. Krist, MD, MPH; Jennifer S. Lin, MD, MCR; Carol M. Mangione, MD, MSPH; Ann E. Kurth, PhD, CNM, MSN, MPH; Francisco A.R. Garc?´a, MD, MPH; Susan J. Curry, PhD; David C. Grossman, MD, MPH; C. Seth Landefeld, MD; John W. Epling Jr., MD, MSEd; and Albert L. Siu, MD, MSPH

Research and Reporting Methods

Abstract: http://annals.org/aim/article/doi/10.7326/M16-2656

American College of Physicians

Related Chronic Fatigue Syndrome Articles:

Biomarker for chronic fatigue syndrome identified by Stanford researchers
Researchers at the Stanford University School of Medicine have created a blood test that can flag chronic fatigue syndrome, which currently lacks a standard, reliable diagnostic test.
Assessment tool predicts chronic fatigue syndrome 6 months after mono
To assess risk factors for chronic fatigue syndrome after mononucleosis, researchers developed and validated a scale for rating the severity of mononucleosis.
Perceptions of chronic fatigue syndrome in the emergency department
Findings from a novel online questionnaire of people with chronic fatigue syndrome (CFS) suggest the majority of these patients do not receive proper care, say researchers from Georgetown University Medical Center in the first investigation of the presentation of CFS in the emergency department.
Insights from metabolites get us closer to a test for chronic fatigue syndrome
A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.
Chronic fatigue syndrome possibly explained by lower levels of key thyroid hormones
A new study reveals that chronic fatigue syndrome, a debilitating condition with unknown causes, can be explained by lower thyroid levels -- but may be distinct from thyroidal disease.
More Chronic Fatigue Syndrome News and Chronic Fatigue Syndrome Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...